Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study
Keywords:
Rucaparib
Recurrent ovarian cancer
Maintenance
Treatment
PARP inhibitor
Editorial note:
© The Author(s) 2022. Open Access
Citation:
Sánchez-Lorenzo, M. L. (María Luisa); Yubero, A. (Alfonso); Barquín, A. (Aranzazu); et al. "Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study". BMC Cancer. 22 (1150), 2022, 1 - 10
Statistics and impact
0 citas en
0 citas en
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.